New gene therapy cuts of tumour’s blood, nutrient supply in miceJune 12th, 2009 - 2:21 pm ICT by ANI
Washington, June 12 (ANI): Researchers at the University of Florida in the U.S. have come up with a novel gene therapy that can cut off a tumour’s blood and nutrient supply.
The researchers have revealed that the new therapy disrupt cancer growth by using a synthetic protein to induce blood clotting.
They tested the technique on mice implanted with human colorectal cancer cells. The treatment reduced tumour volume by 53 percent and slowed cell growth by 49 percent in the animals.
Dr. Bradley S. Fletcher, an assistant professor of pharmacology and therapeutics in the College of Medicine, is the researcher whose team has created the so-called fusion protein to target another protein, called tumour endothelial marker 8 (TEM8), which was recently found to be preferentially expressed in the inner lining of tumour vessels.
Such differences in protein expression enable delivery of drug molecules to the cells that harbour these proteins.
“The protein we created did a very good job of homing to the tumour and binding. By targeting TEM8, we can potentially create a therapy against cancer,” said Stephen Fernando, who recently completed his doctoral studies.
This is the first time that any team of researchers have targeted cancer cells through protein binding to TEM8.
Part of the “fusion protein” created by the UF group binds to TEM8, and the other which promotes thrombosis, or blood clotting.
The researchers delivered genes that encode for it to the lungs of mice. The delivery vehicle was a transposon called Sleeping Beauty, a piece of DNA that can insert new genes stably and efficiently into a cell’s genome.
The lungs then functioned as a factory to produce the protein that later found its way to the target cells in the tumour vessels.
“We felt that TEM8 was an ideal target because it was inside the vessel, preferentially expressed there and unique,” Fletcher said.
Besides promoting blood clots, the treatment was also found to result in reduced tumour vessel density, possibly by interfering with TEM8 function.
The researchers now plan to come up with a method to increase the amounts of the thrombosis-inducing protein produced in the body, and test whether higher dosing leads to unintended blood clots.
They are also planning to explore ways to deliver the protein directly to the sites of interest, rather than through genes that later produce the protein, and apply the method in other areas such as prostate cancer.
A research article on the current study has been published in the journal Cancer Research. (ANI)
- Culprits in life-threatening clotting disorder uncovered - Dec 04, 2010
- Fish oil may hold key to leukaemia cure - Dec 23, 2011
- Melanoma spreads to lungs using body's immune system - Oct 08, 2010
- Snake venom studies paves way for therapies for heart disease, cancer - Jul 30, 2010
- Antioxidant protein promotes clogging of arteries, says study - Jan 11, 2011
- Scientists reveal cancer's hiding spots - Oct 29, 2010
- New 'nanodrug' can attack breast cancer cells from the inside out - Mar 30, 2011
- New 'PiggyBac' mutation tool to identify new cancer genes - Oct 15, 2010
- Silencing 'hedgehog' molecule halts cancer - Jun 06, 2011
- How stressed cells boost production of key blood clotting factor - Feb 05, 2011
- 'Low oxygen levels drive cancer growth' - May 06, 2012
- Targeted photodynamic therapy offers hope for skin cancer patients - Apr 12, 2011
- Genetic change helps lung tumors spread to other parts of the body - Apr 07, 2011
- How two proteins fuse together to trigger cancer - Jan 28, 2011
- 'Jumping genes' make up roughly half of the human genome - Jun 25, 2010
Tags: blood clots, cancer cells, cancer growth, college of medicine, colorectal, delivery vehicle, doctoral studies, drug molecules, fusion protein, gene therapy, good job, human colorectal cancer, novel gene, nutrient supply, protein expression, sleeping beauty, target cells, thrombosis, transposon, university of florida